While clinical trials have demonstrated the benefits of Dolutegravir (DTG) and Lopinavir-Ritonavir (LPV/r) over Nevirapine (NVP)-based regimens, many children are still on NVP-based regimens. Even when LPV/r syrup is available, it is poorly tolerated by children and difficult to store due to its cold chain requirement. This brief provides an overview of EGPAF’s continued work under Unitaid’s POC EID grant to accelerate sustainable access to optimal pediatric ARV formulations in five implementing countries, Côte d’Ivoire, Eswatini, Lesotho, Mozambique and Zimbabwe.
